|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:administeredFrequency
|
every 4 weeks
|
|
gptkbp:approvalYear
|
2021-06-07
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06DX01
|
|
gptkbp:brand
|
gptkb:Aduhelm
|
|
gptkbp:CASNumber
|
1384266-65-4
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:compatibleWith
|
gptkb:Canada
gptkb:European_Union
gptkb:Japan
|
|
gptkbp:controversy
|
FDA approval process
efficacy debated
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:discoveredBy
|
gptkb:Neurimmune
|
|
gptkbp:FDAApprovalType
|
gptkb:accelerated_approval
|
|
gptkbp:firstDescribed
|
2015
|
|
gptkbp:halfLife
|
24.8 days
|
|
gptkbp:hasMolecularFormula
|
C6470H9954N1714O2018S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aducanumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:amyloid_beta
|
|
gptkbp:marketedAs
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:mechanismOfAction
|
reduces amyloid beta plaques
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:human
|
|
gptkbp:notRecommendedFor
|
gptkb:advanced_Alzheimer's_disease
|
|
gptkbp:origin
|
gptkb:Switzerland
|
|
gptkbp:patent
|
gptkb:Biogen
gptkb:Neurimmune
|
|
gptkbp:prescribes
|
mild cognitive impairment due to Alzheimer's disease
mild Alzheimer's dementia
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:amyloid-related_imaging_abnormalities_(ARIA)
confusion
nausea
diarrhea
dizziness
falls
headache
allergic reactions
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:UNII
|
F6F201660Q
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
|
|
gptkbp:withdrawn
|
gptkb:European_Union
|
|
gptkbp:bfsParent
|
gptkb:Aduhelm
|
|
gptkbp:bfsLayer
|
6
|